Charlotte Videbaek

Director/Board Member at CESSATECH A/S

62 year

Health Technology

Commercial Services

Consumer Services

Active connections

Name	Gender	Age	Linked companies	Collaboration
Adam Sinding Steensberg	M	50	CESSATECH A/S	4 years
Martin Olin	M	55	CESSATECH A/S	4 years
Flemming Steen Jensen	M	63	CESSATECH A/S	4 years
Peter Birk	M	59	CESSATECH A/S	4 years
Jes Trygved	M	51	H. LUNDBECK A/S CESSATECH A/S	8 years
Rachel Curtis Gravesen	F	55	CESSATECH A/S	2 years
Steen Henneberg	M	75	CESSATECH A/S	4 years
Louise Bak	F	-	CESSATECH A/S	3 years

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Ulla Hald Buhl	F	60	CESSATECH A/S	1 years
Jakob W. Gotfredsen	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	3 years
Uno Jakob Weber	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	3 years
Christian Torp-Pedersen	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	3 years
Lars Kober	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	3 years
Benedikte Bandak	F	-	CESSATECH A/S	-
Jens Peter Balling	M	-	H. LUNDBECK A/S	-
Anders Götzsche	M	56	H. LUNDBECK A/S	15 years
Iman Barilero	M	-	H. LUNDBECK A/S	-
Jørgen Okkels Nielsen	M	76	H. LUNDBECK A/S	5 years
Marie-Laure Jeanne Antoinette Pochon	F	65	H. LUNDBECK A/S	5 years
Kristian Sibilitz	M	-	H. LUNDBECK A/S	-
Christoffer Erik Lorenzen	M	48	H. LUNDBECK A/S	5 years
Tugba Ceylan	F	-	H. LUNDBECK A/S	1 years
Bettina Nygaard Nielsen	M	47	CESSATECH A/S	-
Inge Holm Lauritzen	F	57	H. LUNDBECK A/S	9 years
Etienne Adriansen	M	60	CESSATECH A/S	-
Per Wold-Olsen	M	76	H. LUNDBECK A/S	4 years
Klaus Bæk Simonsen	M	-	H. LUNDBECK A/S	-
Finn Eggert Sørensen	M	70	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Egil Bodd	M	69	H. LUNDBECK A/S	-
Mads Buhl Axelsen	M	66	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Frank Knudsen	M	66	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Carsten Schou	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Flemming Bent Lindeløv	M	75	H. LUNDBECK A/S	-
Hans Henrik Munch-Jensen	M	64	H. LUNDBECK A/S	8 years
Peter Moldt	M	65	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Peter Bisgaard	M	50	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Helle Størum	F	57	H. LUNDBECK A/S	9 years

Statistics

Country	Connections	% of total
Denmark	37	100.00%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections